Compare LFVN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | XFOR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 324.4M |
| IPO Year | N/A | N/A |
| Metric | LFVN | XFOR |
|---|---|---|
| Price | $6.18 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $35.00 | $28.50 |
| AVG Volume (30 Days) | 153.1K | ★ 638.6K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 143.91 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $228,877,000.00 | $33,979,000.00 |
| Revenue This Year | $1.54 | $1,276.65 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | 16.77 | ★ 2925.74 |
| 52 Week Low | $5.69 | $1.35 |
| 52 Week High | $27.38 | $26.83 |
| Indicator | LFVN | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 52.67 |
| Support Level | $6.21 | $3.48 |
| Resistance Level | $6.71 | $4.08 |
| Average True Range (ATR) | 0.34 | 0.31 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 39.03 | 70.98 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.